VAXCYTE, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
VAXCYTE, INC. (PCVX) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $2.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $2.06M, a 187.31% increase year-over-year.
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $9.29M, a 75.71% increase year-over-year.
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $3.98M, a 57.40% decline year-over-year.
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $717.00K, a 26.90% increase year-over-year.
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $10.99M, a 23.10% decline from fiscal 2024.
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $14.29M, a 268.73% increase from fiscal 2023.
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $3.88M, a 350.17% increase from fiscal 2022.
- VAXCYTE, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $861.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.06M 10-Q · filed 2026-08-05 | $11.36M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $9.29M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $10.99M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $3.98M 10-Q · filed 2025-11-04 | $4.69M derived: sum of 2 quarters · filed 2026-08-05 | $9.98M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $717.00K 10-Q · filed 2026-08-05 | $6.01M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $5.29M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $14.29M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $9.34M 10-Q · filed 2025-11-04 | $9.90M derived: sum of 2 quarters · filed 2025-11-04 | $13.21M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $565.00K 10-Q · filed 2025-11-04 | $3.87M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $3.31M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $3.88M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $861.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |